AS 1892802ROCK inhibitor,potent and ATP-competitive CAS# 928320-12-1 |
- Coptisine sulfate
Catalog No.:BCN2286
CAS No.:1198398-71-8
- Procyanidin B2
Catalog No.:BCN6315
CAS No.:29106-49-8
- Onjisaponin B
Catalog No.:BCN2741
CAS No.:35906-36-6
- Gypenoside XLIX
Catalog No.:BCN1207
CAS No.:94987-08-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 928320-12-1 | SDF | Download SDF |
| PubChem ID | 56593240 | Appearance | Powder |
| Formula | C20H19N3O2 | M.Wt | 333.38 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 25 mM in ethanol | ||
| Chemical Name | 1-(2-hydroxy-1-phenylethyl)-3-(4-pyridin-4-ylphenyl)urea | ||
| SMILES | C1=CC=C(C=C1)C(CO)NC(=O)NC2=CC=C(C=C2)C3=CC=NC=C3 | ||
| Standard InChIKey | WDTFYYZHMRBVHK-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H19N3O2/c24-14-19(17-4-2-1-3-5-17)23-20(25)22-18-8-6-15(7-9-18)16-10-12-21-13-11-16/h1-13,19,24H,14H2,(H2,22,23,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent, ATP-competitive ROCK inhibitor (IC50 values are 52, 57 and 122 nM for human ROCK2, rat ROCK2 and human ROCK1 respectively by ELISA); also inhibits PKAC-α and PRKX (IC50 values are 200 and 325 nM respectively). Exhibits analgesic effects in rat models of inflammatory (AIA) and noninflammatory (MIA) arthritic pain. Orally bioavailable. |
AS 1892802 Dilution Calculator
AS 1892802 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | 59.9916 mL | 74.9895 mL |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | 11.9983 mL | 14.9979 mL |
| 10 mM | 0.3 mL | 1.4998 mL | 2.9996 mL | 5.9992 mL | 7.499 mL |
| 50 mM | 0.06 mL | 0.3 mL | 0.5999 mL | 1.1998 mL | 1.4998 mL |
| 100 mM | 0.03 mL | 0.15 mL | 0.3 mL | 0.5999 mL | 0.7499 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AS 1892802 is a potent and selective inhibitor of ROCK with IC50 values of 52, 57 and 122 nM for human ROCK2, rat ROCK2 and human ROCK1, respectively [1].
Rho kinase (ROCK) is a serine-threonine kinase and is a downstream effector of Rho, a small GTP-bound protein. ROCK phosphorylates target proteins such as myosin light chain kinase and LIM kinase and regulates cellular shape modification, migration, growth and contraction [2].
AS 1892802 is a potent ROCK inhibitor. AS 1892802 inhibited ROCK1 and ROCK2 with IC50 values of 1.69 and 0.10 μM, respectively [3]. In ATDC5 cells, AS1892802 induce chondrocyte differentiation. In HIG82 cells, AS1892802 significantly inhibited prostaglandin E2 production induced by IL-1β or bradykinin [4].
In both an adjuvant-induced arthritis (AIA) rat model and a monoiodoacetate (MIA) -induced arthritis (MIA) rat model, AS1892802 showed potent antinociceptive effect with ED50 value of 0.15 mg/kg [1]. In monoiodoacetate-induced arthritis and streptozotocin-induced neuropathy models, AS1892802 showed analgesic effect [2]. In MIA-injected rats, the mRNA levels of ROCK I and II increased in knee joints. AS1892802 significantly inhibited cartilage damage in a dose-dependent way [4].
References:
[1]. Yoshimi E, Kumakura F, Hatori C, et al. Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. J Pharmacol Exp Ther, 2010, 334(3): 955-963.
[2]. Yoshimi E, Yamamoto H, Furuichi Y, et al. Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. J Pharmacol Sci, 2010, 114(1): 119-122.
[3]. Li R, Martin MP, Liu Y, et al. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. J Med Chem, 2012, 55(5): 2474-2478.
[4]. Takeshita N, Yoshimi E, Hatori C, et al. Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents. J Pharmacol Sci, 2011, 115(4): 481-489.
- MN 64
Catalog No.:BCC6489
CAS No.:92831-11-3
- Boc-D-Asp-OBzl
Catalog No.:BCC3370
CAS No.:92828-64-3
- 3-Chloro-1-(4-octylphenyl)-propanone
Catalog No.:BCN2249
CAS No.:928165-59-7
- Tenacissoside F
Catalog No.:BCN4472
CAS No.:928151-78-4
- Alisol O
Catalog No.:BCN3362
CAS No.:928148-51-0
- Golvatinib (E7050)
Catalog No.:BCC4423
CAS No.:928037-13-2
- RAF265
Catalog No.:BCC3677
CAS No.:927880-90-8
- DPNI-caged-GABA
Catalog No.:BCC5957
CAS No.:927866-58-8
- KC7F2
Catalog No.:BCC2434
CAS No.:927822-86-4
- Glochicoccin D
Catalog No.:BCN4471
CAS No.:927812-23-5
- Motolimod (VTX-2337)
Catalog No.:BCC6497
CAS No.:926927-61-9
- Toll-like receptor modulator
Catalog No.:BCC2007
CAS No.:926927-42-6
- IRAK inhibitor 2
Catalog No.:BCC1655
CAS No.:928333-30-6
- PF-03716556
Catalog No.:BCC2084
CAS No.:928774-43-0
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
- Pracinostat (SB939)
Catalog No.:BCC2152
CAS No.:929016-96-6
- GSK461364
Catalog No.:BCC3788
CAS No.:929095-18-1
- 7-Oxo-ganoderic acid Z
Catalog No.:BCN7973
CAS No.:929248-72-6
- LUF 6283
Catalog No.:BCC6318
CAS No.:92933-48-7
- Fmoc-Tyr-OH
Catalog No.:BCC3562
CAS No.:92954-90-0
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
- Sessilifoline A
Catalog No.:BCN4473
CAS No.:929637-35-4
- Cucumegastigmane I
Catalog No.:BCN4474
CAS No.:929881-46-9
Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.[Pubmed:22272748]
J Med Chem. 2012 Mar 8;55(5):2474-8.
Using high concentration biochemical assays and fragment-based screening assisted by structure-guided design, we discovered a novel class of Rho-kinase inhibitors. Compound 18 was equipotent for ROCK1 (IC(50) = 650 nM) and ROCK2 (IC(50) = 670 nM), whereas compound 24 was more selective for ROCK2 (IC(50) = 100 nM) over ROCK1 (IC(50) = 1690 nM). The crystal structure of the compound 18-ROCK1 complex revealed that 18 is a type 1 inhibitor that binds the hinge region in the ATP binding site. Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells.
Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.[Pubmed:20534789]
J Pharmacol Exp Ther. 2010 Sep 1;334(3):955-63.
Rho kinase (ROCK) is involved in various physiological functions, including cell motility, vasoconstriction, and neurite extension. Although a functional role of ROCK in nociception in the central nervous tissue has been reported in neuropathy, the peripheral function of this protein in hyperalgesia is not known. In this study, antinociceptive effects of AS1892802 [1-[(1S)-2-hydroxy-1-phenylethyl]-3-[4-(pyridin-4-yl)phenyl]urea], a novel and highly selective ROCK inhibitor, were investigated in two rat models of arthritis. Orally administered AS1892802 exhibited potent antinociceptive effect in both an adjuvant-induced arthritis (AIA) model (inflammatory arthritis model) and a monoiodoacetate-induced arthritis (MIA) model (noninflammatory arthritis model), with an ED(50) of 0.15 mg/kg (MIA model). Fasudil, a ROCK inhibitor, and tramadol were also effective in both models; however, diclofenac was effective only in the AIA model. The onset of antinociceptive effect of AS1892802 was as fast as those of tramadol and diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. Because AS1892802 rarely penetrates the central nervous tissue and is also effective by intra-articular administration, it seemed to function peripherally. These results suggest that AS1892802 has an attractive analgesic profile for the treatment of severe osteoarthritis pain.
